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The signal value of Singer, Siegler, and Pellagrino's arti-
cle, "Clinical ethics revisited," [1;  [http://www.biomed-
central.com/1472-6939/2/1] ] appears to lie in its
recognition of the subdiscipline as the authors define it.
Certainly, a series of critiques posted with the article [2]
question the article's central thrust, that while clinical
ethics remains a developing field of medicine that its
general tenants are sound. Most damning, perhaps, is
the original author's admission that, "if the goal of clini-
cal ethics is to improve patient care and outcomes, there
is scant evidence this has been achieved." If that is true -
and it is a point upon which both critics and authors
agree - then arguing as do Singer et al. for increased
funding, more research, and a stronger educational pos-
ture is at best premature.
As Virginia Sharpe notes [2], the clinical ethic espoused
by the authors is limited and perhaps incomplete from
the start. Singer et al. insist that "clinical ethics is not
founded in philosophy, law, or theology but, instead, is a
sub-discipline of medicine, centering upon the doctor-
patient relationship" [1, 2]. This assumes that only the
doctor-patient relationship is important. The authors
thus exclude - critically and I believe incorrectly - not
only other professional "healing relationships" (with
nurses, for example) but also those involving family car-
egivers and the institutional context in which care is pro-
vided for patients and through those caregivers.
And yet these often affect not only patient care and well-
being, but also clinical decision making. The needs and
perspectives of patient surrogates effect, for example,
questions of how patients with chronic progressive con-
ditions should be treated (ALS, MS, etc.), and of course,
the issues of continuance for those in a coma or a persist-
ent vegetative state. A clinical ethics defined as involving
only doctor-patient relationships is thus necessarily in-
complete and limited from the start.
The assumption that clinical ethics is easily divorced
from either philosophical or legal issues is similarly
problematic. This "clinical-not philosophical, social, or
legal" approach may explain the limits of the approach
the original authors advance. The social perspectives ar-
gued in general bioethical appraochs, the social restric-
tions presented in law and the general views of
humanness and personhood advanced by theologians
(and philosophically trained ethicists) all directly affect
clinical medicine and the ethics of its practice. Proce-
dures ranging from therapeutic or elective abortion, to
palliative care or treat modalities for patients with
chronic progressive conditions (MS, ALS, etc.) are at
once clinical, philosophical, legal and theoretical prob-
lems requiring broader rather than narrower address.
Indeed, it is precisely because of the interplay between
clinical decision making and social concerns that bioeth-
ics first was created. In the 1960s, for example, a purely
clinical ethic was incapable of addressing the rationing of
dialysis facilities among the many patients then under-
going dialysis in the USA. It was this debate that intro-
duced moral philosophers as clinical commentators to
the greater public [3]. Things haven't changed overmuch
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are unclear socially or counter-indicated by law, then
their clinical implementation will be problematic [4].
There is in the original article - but not in the critiques of-
fered to date - a general refusal to acknowledge the im-
portance of the social context in which medical decision
making occurs. Here, Benetar's comments [5] are espe-
cially damning, and worth quoting: "The growth of
bioethics has taken place in an era when medicine, par-
ticularly in the USA, has been transformed into a busi-
ness, and health care has been commodified and
bureaucratised." This may explain why, there has been a
"loss of trust in health care professionals." Why trust
those whose relation to the patient is in fact defined by
commercial relations rather than historical associations
of care and caring? And it may be that the commodifica-
tion of health that has affected clinical outcomes by af-
fecting treatment decisions. It almost certainly has
affected patient-health professional relationships.
Contemporary medical ethics is redolent with cases in
which the needs of the patient are opposed by the often
commercially defined practice guidelines of hospitals
and funding agencies. In his critique Daar cites the Gels-
inger case, "in which a teenager died while undergoing
gene therapy in the hands of researchers who allegedly
had conflicts of interest and failed to report to the au-
thorities important previous research data that may have
contributed to the fatal outcome [6]".
Another case in which the primacy of patient care
seemed to have been suborned by commercial issues
drives home the point. At the Hospital for Sick Children,
in Toronto, Canada, the Olivieri case saw a physician os-
tracized and condemned for publicly announcing the
dangers of a disease she was testing among juvenile pa-
tients with Thalassemia Major [7]. Dr. Olivieri argued
that as a physician her primary duty was to her patients,
not the drug company that funded her work or the hospi-
tal that employed her [8]. For this she was suspended
from her work by the hospital.
Singer et al. lament the failure of public engagement by
clinical ethicists. But the truth is that too often those in-
volved in clinical policy do not wish public dialog at all.
This was underscored when the Cleveland Clinic Foun-
dation's sought to implement a non-beating heart proto-
col - commonly known as the Pittsburgh Protocol - in the
1990s. It was done without public input, or apparently,
legal review. The program was terminated after an inves-
tigation by the local prosecutor's office became a national
issue. The use of specific drugs to facilitate organ extrac-
tion from respiring patients was seen as potentially ac-
tionable under state homicide statutes.
A CCF bioethicist, arguing the clinical efficacy of the
plan, later described this as the imposition of unwanted
and unnecessary public and legal attention to a funda-
mentally clinical issue. If clinically sound protocols were
so treated, CCF ethicist George Aggich argued, "The fu-
ture of bioethics may be not in the media spotlight, but in
shadows where the quality of everyday patient care is en-
hanced [9]." What Aggich ignored was both the social
and legal climate in which medical protocols exist. As
Ankney notes, public perception has a real effect on do-
nation [10, for example. The problem was not, in the end,
with public exposure but with the institution's failure to
involve interested parties - local citizenry and their rep-
resentatives - in a dialog over policy [11] with profound
clinical and social implications.
It would seem from this and the other critiques offered
by readers of the original paper that a methodologically
based clinical ethics is a failure. It has served the needs of
professionals but not the patients, or their carers. It thus
in too many cases ignores the social context in which
medicine is practiced and in which patients receive or are
denied care. It ignores, in the original authors' formula-
tion, the broad complex of healing relationships that
contribute greatly to a patient's condition, and often his
or her medical outcome. If clinical ethics is, in fact, a sub-
discipline of medicine, it is one that necessarily must in-
volve social, legal, and sometimes theological percep-
tions.
In the end, clinical ethics needs to be redefined in a man-
ner that acknowledges that medicine is more than meth-
odology, that patient outcomes result from a complex of
factors extending beyond the "doctor-patient relation-
ship." Before the subdiscipline can evolve into an effec-
tive perspective it therefore must engage the complex of
economic and social factors influencing patient health
and well-being.
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